Adronic IV Infusion

About Adronic 4 mg/5 ml IV Infusion

Adronic 4 mg/5 ml is a iv infusion product of Aristopharma Ltd. that contains Zoledronic Acid [For hypercalcemia]. Adronic is used to treat hypercalcemia of malignancy, which is a high level of calcium in the blood caused by cancer.

There are 2 brands of Zoledronic Acid [For hypercalcemia] listed in Bangladesh. 1 of them has a lower unit price than Adronic. The lowest listed price is Acidron 4 mg/5 ml IV Infusion at ৳ 5000.00 per unit.

What is Adronic 4 mg/5 ml IV Infusion?

Made by Aristopharma Ltd., Adronic is a iv infusion whose active ingredient is Zoledronic Acid [For hypercalcemia]. It is given by intravenous infusion and works mainly on bone by reducing the activity of cells that break down bone. It is used in the management of raised blood calcium associated with cancer and in some bone conditions related to tumours. Ask your doctor or pharmacist if you are unsure about it.

Uses of Adronic

Adronic is used to treat hypercalcemia of malignancy, which is a high level of calcium in the blood caused by cancer. It is also used for bone metastases from solid tumours, osteolytic lesions in multiple myeloma, and several bone conditions including osteoporosis and Paget's disease of bone. It belongs to the bisphosphonate group of medicines. The doctor decides whether it is appropriate for a particular patient.

How to use Adronic

Blood tests for calcium, phosphate, magnesium, potassium and kidney function may be checked during treatment. Take Adronic 4 mg/5 ml iv infusions exactly as your doctor tells you. Complete the course exactly as prescribed. The doctor decides the dose and course.

Side effects of Adronic

Serious problems can include jaw bone damage and kidney problems. Common side effects after a dose can include headache, nausea, vomiting, constipation, loss of appetite, tiredness, fever, flu-like symptoms, bone pain, muscle pain and joint pain. Some people may have low calcium or low phosphate levels in the blood. Tell your doctor if any side effect bothers you or does not go away. Tell your doctor promptly about jaw pain, tooth problems, fever, or any unusual symptoms after treatment.

Safety and precautions

Adronic is not for people with severe kidney problems, low blood calcium or an allergy to bisphosphonates. The doctor will monitor kidney function and blood mineral levels. Good hydration is important before and after the infusion. Tell your doctor about all the other medicines you take.

Frequently asked questions

What is Adronic used for?

Adronic is used to treat hypercalcemia of malignancy, which is a high level of calcium in the blood caused by cancer. It is also used for bone metastases from solid tumours, osteolytic lesions in multiple myeloma, and several bone conditions including osteoporosis and Paget's disease of bone.

How should I take Adronic?

Blood tests for calcium, phosphate, magnesium, potassium and kidney function may be checked during treatment. Take Adronic 4 mg/5 ml iv infusions exactly as your doctor tells you.

Can Adronic cause side effects?

Serious problems can include jaw bone damage and kidney problems. Common side effects after a dose can include headache, nausea, vomiting, constipation, loss of appetite, tiredness, fever, flu-like symptoms, bone pain, muscle pain and joint pain.

What is the price of Adronic?

The listed price is ৳ 6500.00.

Indications

Zoledronic Acid is indicated in:
  • Hypercalcaemia of malignancy, 
  • Bone metastases associated with solid tumours, Osteolytic lesions associated with multiple myeloma, 
  • Corticosteroid-induced osteoporosis, Increase bone mass in men with osteoporosis, Osteoporosis in postmenopausal women
  • Paget's disease of bone
  • Prophylaxis of postmenopausal osteoporosis

Pharmacology

Zoledronic acid belongs to the class of nitrogen-containing bisphosphonates and acts primarily on bone. It is an inhibitor of osteoclast-mediated bone resorption. The action of bisphosphonates on bone is based on their high affinity for mineralized bone. Intravenously administered Zoledronic acid is rapidly distributed to bone. The main molecular target of Zoledronic acid in the osteoclast is the enzyme farnesyl pyrophosphate synthase, but this does not exclude other mechanisms. Clinical studies in tumour-induced hypercalcemia demonstrated that the effect of Zoledronic acid is characterized by decreases in serum calcium and urinary calcium excretion. In addition to its inhibitory activity against bone resorption, Zoledronic acid also possesses anti-tumour activity, anti-angiogenic activity, anti-pain activity, cytostatic and pro-apoptotic activity on tumour cells and synergistic cytostatic effect with other anti-cancer drugs. There was no accumulation of the active substance in plasma after multiple doses given every 28 days. Zoledronic acid is not metabolized and is excreted unchanged via the kidney.

Dosage & Administration

Hypercalcemia of malignancy: The maximum recommended dose of Zoledronic Acid in hypercalcemia of malignancy (serum calcium 12 mg/dl or 3.0 mmol/l) is 4 mg. The 4 mg dose must be given as a single-dose intravenous infusion. Dose adjustment of Zoledronic Acid is not necessary in treating patients for hypercalcemia of malignancy presenting with mild-to-moderate renal impairment. Re-treatment with Zoledronic Acid may be considered if serum calcium does not return to normal after initial treatment. It is recommended that a minimum of 7 days elapse before re-treatment, to allow for full response to the initial dose. 

Multiple myeloma and bone metastases of solid tumors: The recommended dose of Zoledronic Acid in patients with multiple myeloma and metastatic bone lesions from solid tumors is 4 mg infused every 3-4 weeks. Patients should also be administered an oral calcium supplement of 500 mg and 400 IU of Vitamin-D daily.

Interaction

In clinical studies, Zoledronic acid has been administered concomitantly with commonly used anticancer agents, diuretics, antibiotics and analgesics without interactions. Caution is advised when Zoledronic acid are administered with aminoglycosides, since these agents may have an additive effect to lower serum calcium level for prolonged periods. In multiple myeloma patients, the risk of renal dysfunction may be increased when Zoledronic acid is used in combination with thalidomide. Concomitant use of loop diuretics with Zoledronic acid increases the risk of hypocalcemia. Caution is indicated when Zoledronic acid is used with other potentially nephrotoxic drugs.

Contraindications

The drug is contraindicated if patients have hypersensitivity to the active substance or to any of the excipients or to any bisphosphonates; severe renal impairment (Creatinine clearance <30 ml/min); pregnancy and lactation.

Side Effects

The post-dose side-effects are headache, nausea, anorexia, fatigue, osteonecrosis of jaw, anemia, bone pain, constipation, fever, vomiting, flu-like syndrome, hypocalcemia, myalgia, arthralgia and hypophosphataemia.

Pregnancy & Lactation

Zoledronic acid is contraindicated during pregnancy and in breast-feeding women. It is also not recommended for use in children and adolescents below 18 years of age.

Precautions & Warnings

Patients must be appropriately hydrated prior to administration of Zoledronic Acid. This is especially important in the elderly and for patients receiving diuretic therapy. Adequate hydration can be achieved by the patient drinking two glasses of fluid (such as water) before and after the infusion. Serum levels of calcium, phosphate, magnesium and potassium, as well as serum creatinine should be carefully monitored after initiating Zoledronic Acid therapy. If hypocalcemia, hypophosphatemia or hypomagnesemia occurs, short-term supplemental therapy may be necessary. Moreover, careful renal function monitoring should be considered.

Overdose Effects

Clinical experience with acute over dosage is limited. Over dosage may cause hypocalcemia, hypophosphatemia, and hypomagnesemia. In such case, reduction in serum levels of calcium, phosphorus, and magnesium should be corrected by intravenous administration of calcium gluconate, potassium or sodium phosphate and magnesium sulfate respectively.

Storage Conditions

Store below 30° C prior to opening. Protect from moisture and light. Zoledronic Acid must be kept out of the reach and sight of children.

Alternative brands of Zoledronic Acid [For hypercalcemia]

Other brands with the same generic name, cheapest first.

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.